BeiGene To Cash In On Brukinsa’s Potential As Best-In-Class BTKi After CLL Approvals
As EU Footprint Grows
Executive Summary
The Chinese multinational believes Brukinsa could beat competition from the likes of J&J and AstraZeneca to become the BTKi of choice in chronic lymphocytic leukemia, the drug’s latest indication on both sides of the pond.